An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bicycle Therapeutics (NASDAQ: BCYC) has announced that interim Phase I results from its Phase I/II trial of BT5528, a second-generation Bicycle® Toxin Conjugate targeting EphA2, will be presented at the AACR-NCI-EORTC Virtual International Conference on October 7-10, 2021. The plenary oral presentation will be conducted by Dr. Meredith McKean from the Sarah Cannon Research Institute. The company will also host a conference call on October 7, 2021, at 3:00 p.m. ET to discuss these results and updates from the BT8009 program.
Positive
None.
Negative
None.
- Company to host conference call on Thursday, October 7, 2021 at 3:00 p.m. ET
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that interim Phase I results from its Phase I/II trial of BT5528, a second-generation Bicycle® Toxin Conjugate (BTC™) targeting EphA2, has been selected for a plenary oral presentation at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, being held October 7-10, 2021. The Company will host a conference call to discuss the results and provide an update on preliminary findings from the BT8009 program on Thursday, October 7, 2021 at 3:00 p.m. ET.
AACR-NCI-EORTC Plenary Oral Presentation Details:
Title: A first in class phase I/II Study of the Novel Bicyclic Peptide and MMAE Conjugate, BT5528, in patients with Advanced Malignancies Associated with EphA2 Expression
Presenter: Meredith McKean, M.D., Sarah Cannon Research Institute at Tennessee Oncology
Session Title: Tumor-targeted Conjugates: A Growing Family
Date/Time: Thursday, October 7 at 12:50 p.m. ET
Conference Call Details
Bicycle Therapeutics will host a conference call and webcast on Thursday, October 7 at 3:00 p.m. ET to review the data being presented and provide an update on preliminary findings from the BT8009 program. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2287246. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com.
About Bicycle Therapeutics Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2, and BT8009, a second-generation BTC™ targeting Nectin-4, a well-validated tumor antigen, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC™ that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Centre for Drug Development of Cancer Research UK. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.
What are the Phase I results for Bicycle Therapeutics' BT5528 being presented?
The interim Phase I results for BT5528, a second-generation Bicycle Toxin Conjugate targeting EphA2, will be presented at the AACR-NCI-EORTC Conference from October 7-10, 2021.
When is the Bicycle Therapeutics conference call regarding BT5528 results?
Bicycle Therapeutics will host a conference call on October 7, 2021, at 3:00 p.m. ET to discuss the BT5528 results and updates on the BT8009 program.
Who is presenting the BT5528 results at the AACR-NCI-EORTC Conference?
Dr. Meredith McKean from the Sarah Cannon Research Institute is presenting the BT5528 results at the AACR-NCI-EORTC Conference.
What is the significance of the BT5528 presentation for Bicycle Therapeutics (BCYC)?
The presentation of BT5528 results at a major conference enhances Bicycle Therapeutics' visibility and credibility in the oncology space, highlighting their innovative drug development efforts.
Where can I access the Bicycle Therapeutics conference call?
The conference call can be accessed by dialing (800) 377-9118 domestically or (409) 937-8920 internationally, using Conference ID 2287246.
Bicycle Therapeutics plc American Depositary Shares
